Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,382
Change Today +10.00 / 0.73%
Volume 58.5K
As of 10:24 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Open
$1,372
Previous Close
$1,372
Day High
$1,392
Day Low
$1,370
52 Week High
09/4/14 - $2,595
52 Week Low
11/25/14 - $1,160
Market Cap
502.9M
Average Volume 10 Days
71.8K
EPS TTM
$-0.24
Shares Outstanding
36.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company’s lung disease products include Glassia used in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency (AATD); Bramitob to manage chronic pulmonary infection; and FOSTER for regular treatment of asthma. Its immunoglobulin products comprise KamRAB for prophylaxis against rabies infection; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for the treatment of various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. The company also provides critical care products, such as Heparin Lock Flush to maintain patency of indwelling IV catheter; Heparin sodium injection to treat thrombo-embolic disorders; Kamacaine 0.5% used as anesthesia or analgesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; and Albumin for maintenance of circulating blood volume. In addition, it offers Transferrin for diagnostic assays and cell cultures; and coagulation factors, including Factor VIII, Factor IX, and Human Transferrin. Further, the company develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary diseases, graft-versus-host diseases, and transplantations. It has collaboration partnerships with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

302 Employees
Last Reported Date: 04/28/15
Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $207.0K
Co-Founder and Deputy Executive Chairman
Total Annual Compensation: $455.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $234.0K
Senior Vice President of Operations
Total Annual Compensation: $242.0K
Vice President of Research and Development
Total Annual Compensation: $212.0K
Compensation as of Fiscal Year 2014.

kamada ltd (KMDA) Key Developments

Kamada Ltd. Appoints Michael Berelowitz to its Board of Directors

Kamada Ltd. announced that the Company has appointed Michael Berelowitz, M.D. to its Board of Directors. With Dr. Berelowitz' appointment, Kamada's Board will have ten directors. Dr. Berelowitz brings over 40 years of clinical development and academic research experience, including 15 years of pharmaceutical development experience with Pfizer Inc. While at Pfizer, Dr. Berelowitz was Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit.

Kamada Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Year Ending December 31, 2015

Kamada Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. Total revenues for the second quarter of 2015 of $19.2 million compared with $15.8 million for the second quarter of 2014. For the second quarter of 2015, the Company reported an operating loss of $2.5 million compared with an operating loss of $7.9 million for the second quarter of 2014. The company recorded a net loss for the second quarter of 2015 of $2.3 million or $0.06 per share, compared with a net loss of $8.4 million or $0.23 per share for the same period in 2014. The adjusted net loss for the second quarter of 2015 was $1.8 million compared with an adjusted net loss of $7.4 million for the same period in 2014. Adjusted EBITDA for the second quarter of 2015 was a loss of $1.1 million compared with a loss of $6.2 million for the second quarter of 2014. Loss before taxes on income was $2,342,000 against $8,351,000 a year ago. Net cash used in operating activities was $5,667,000 against $3,733,000 a year ago. Purchase of property and equipment was $823,000 against $919,000 a year ago. Total revenue for the first half of 2015 of $28.2 million compared with $29.0 million for the first half of 2014. Operating loss for the first six months of 2015 of $8.2 million compared with operating loss of $10.6 million for the first six months of 2014. Net loss for the first half of 2015 was $7.6 million or $0.21 per share, compared with a net loss of $11.5 million or $0.32 per share for the same period in 2014. Adjusted EBITDA for the first six months of 2015 was negative $5.6 million, compared with negative $7.2 million for the same period last year. Loss before taxes on income was $7,636,000 against $11,450,000 a year ago. Net cash used in operating activities was $7,675,000 against $5,279,000 a year ago. Purchase of property and equipment was $1,332,000 against $1,535,000 a year ago. For the year ending December 31, 2015, Kamada expects total revenue to be between $70 million and $73 million.

Kamada Ltd., Q2 2015 Earnings Call, Jul 30, 2015

Kamada Ltd., Q2 2015 Earnings Call, Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 1,382.00 +10.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €36.12 EUR +0.005
View Industry Companies
 

Industry Analysis

KMDA

Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit www.kamada.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.